https://scholars.lib.ntu.edu.tw/handle/123456789/568673
標題: | Natural course and treatment of hepatitis D virus infection | 作者: | Hsieh T.-H. CHUN-JEN LIU DING-SHINN CHEN PEI-JER CHEN |
公開日期: | 2006 | 出版社: | Scientific Communications International Ltd | 卷: | 105 | 期: | 11 | 起(迄)頁: | 869-881 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Hepatitis D virus (HDV) is a subviral satellite with hepatitis B virus (HBV) as its natural helper virus. After entry into hepatocytes, it utilizes host cellular enzymes to replicate by a double-rolling-circle mechanism. HDV is most often transmitted by contact with contaminated blood and body fluid, similar to HBV infection. Approximately 5% of the global HBV carriers are coinfected with HDV, leading to a total of 10-15 million HDV carriers worldwide. HDV infection can occur concurrently with HBV infection (coinfection) or in a patient with established HBV infection (superinfection). The pathogenesis of HDV remains controversial. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide. At present, therapy for chronic HDV infection is by the use of interferon-α. Compared to chronic hepatitis B or C, CHD treatment requires a higher dosage and a longer duration of treatment, and post-treatment relapses are common. In order to prevent the progression of CHD and its related morbidity and mortality, more effective treatments are needed. ?2006 Elsevier & Formosan Medical Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984555060&doi=10.1016%2fS0929-6646%2809%2960172-8&partnerID=40&md5=1727fa2e07b51905cedf0dfc544aa068 https://scholars.lib.ntu.edu.tw/handle/123456789/568673 |
ISSN: | 0929-6646 | DOI: | 10.1016/S0929-6646(09)60172-8 | SDG/關鍵字: | aciclovir; alpha interferon; alpha2a interferon; alpha2b interferon; deoxyribonucleotide; famciclovir; humoral thymus factor; interferon; lamivudine; nucleoside analog; nucleotide derivative; peginterferon; peginterferon alpha2b; ribavirin; clinical feature; clinical trial; combination chemotherapy; delta agent hepatitis; diagnostic procedure; disease course; drug efficacy; drug megadose; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis delta virus; human; infection prevention; life cycle; liver cell; monotherapy; morbidity; mortality; nonhuman; pathogenesis; prevalence; relapse; review; RNA interference; seroepidemiology; superinfection; virus carrier; virus morphology; virus transmission |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。